nyxol | 合法醫療器材資訊網
Nyxol®isapreservative-freeophthalmicsolutioncontaining0.75%phentolamine(or1%phentolaminemesylate),anonselectivealphaadrenergicantagonist ...,05.18.21.OcuphireGrantedTwoNewUSPatentsCoveringLate-StageDrugCandidateNyxolIncludingfortheTreatmentofPresbyopia.Source:Ocuphire ...,2021年1月20日—UseofNyxoleyedropsproducedastatisticallysignificant20%meanreductionorapproximately1mminpupildiameterunderdaytimeand ...,2021年5月12日—NyxolhasPotentialtobeaNewEyeDropTreatmentOptionforPresbyopia.Top-LineVEGA-...
ocuphire farmington hills apx3330 ocuphire pharma ocuphire pharma news ocuphire pharma cvr ocuphire corporate presentation rexn stock eyenovia Ocuphire Pharma Inc apexian pharmaceuticals Rexahn Pharmaceuticals apx2009 ocuphire pharma ocuphire pipeline ocuphire news ocuphire investor relations ocuphire stock rexahn pharmaceutical rexahn pharmaceuticals news ocuphire pharma cvr Ocuphire Pharma Inc APX3330 Tasly pharmaceuticals inc Supernus Pharmaceuticals Visus therapeutics Omeros corporation Eyenovia ENTX rexahn pharmaceuticals stock news inc investor relations ADTX Tasly Pharmaceuticals inc Impedance Testing and Hearing Screening system kowa vk-2 download 腸骨動脈血管支架置放術 “OG” Electrical Stimulator IVES one lambda logo labscreen covid plus Roche Diagnostics ultr
Nyxol : | 合法醫療器材資訊網
Nyxol® is a preservative-free ophthalmic solution containing 0.75% phentolamine (or 1% phentolamine mesylate), a nonselective alpha adrenergic antagonist ... Read More
Nyxol – Eyewire News | 合法醫療器材資訊網
05.18.21. Ocuphire Granted Two New US Patents Covering Late-Stage Drug Candidate Nyxol Including for the Treatment of Presbyopia. Source: Ocuphire ... Read More
Ocuphire Announces Publication of ORION | 合法醫療器材資訊網
2021年1月20日 — Use of Nyxol eye drops produced a statistically significant 20% mean reduction or approximately 1 mm in pupil diameter under daytime and ... Read More
Ocuphire Completes Enrollment in VEGA | 合法醫療器材資訊網
2021年5月12日 — Nyxol has Potential to be a New Eye Drop Treatment Option for Presbyopia. Top-Line VEGA-1 Data Expected by End of Q2 2021. Read More
Ocuphire Granted Two New U.S. Patents Covering Late | 合法醫療器材資訊網
2021年5月18日 — Nyxol for Treatment of Presbyopia: U.S. Patent No. 10,993,932 issued on May 4, 2021 with claims to methods of treating presbyopia using a ... Read More
Ocuphire to Host Key Opinion Leader Event on Nyxol® as a | 合法醫療器材資訊網
2021年5月20日 — Highlights of Recent Positive Data from Nyxol's Phase 3 Registration Trial Roundtable Discussion by 3 KOLs with Unique Perspectives and ... Read More
Ocuphire's Nyxol in mydriasis jumps nine points in FDA ... | 合法醫療器材資訊網
2021年3月25日 — The FDA LoA for Ocuphire Pharma's Nyxol in mydriasis rose by nine points after positive Phase III data, according to GlobalData's LoA update. Read More
Reversal of Mydriasis Phase 2 Clinical Trial with Nyxol ... | 合法醫療器材資訊網
Randomized, 2-arm cross-over, double-masked Phase 2b study in approximately 32 healthy subjects, evaluating safety and efficacy of Nyxol in subjects with ... Read More
VEGA | 合法醫療器材資訊網
Randomized, Placebo-Controlled, Double-Masked Study of the Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) With Low-Dose (0.4%) ... Read More
相關資訊整理
【“惟視艾”眼用黏彈體手術裝置】許可證字號:衛部醫器輸字第029981號
器材品名:“惟視艾”眼用黏彈體手術裝置許可證字號:衛部醫器輸字第029981號註銷狀態:註銷日期:註銷理由:有效日期:2022/07/24發...